Epigenetics in prostate cancer.
Prostate Cancer., 2011:580318 (2011)
Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: implications for future genomic research in minority populations.
Cancer., Feb;118(4):1075-82 (2012)
Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.
J. Urol., Jan;187(1):302-9 (2012)
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
J. Clin. Oncol., Apr;29(12):1525-30 (2011)
Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications.
Future Oncol., Dec;3(6):665-82 (2007)
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Clin. Cancer Res., Oct;12(20 Pt 1):6094-9 (2006)
Germ cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease.
Urol. Oncol., 23(4):293-302 (2005)
Combined chemoradiotherapy in small cell lung cancer.
Hematol. Oncol. Clin. North Am., Apr;19(2):321-42, vii (2005)
DNMT1: An emerging target in the treatment of invasive urinary bladder cancer.
Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Hum Vaccin Immunother., Apr;8(4):534-9 (2012)
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate.
J. Clin. Oncol., Jan;27(3):460-3 (2009)
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.
Ann. Oncol., Dec;20(12):1971-6 (2009)